Efficacy and Safety of Low-Dose Decitabine Combined with Ibrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Objective:To observe the efficacy and safety of low-dose decitabine combined with ibrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma.Methods:The clinical data(including general information,pathological diagnosis,treatment course,toxicity and survival)of patients with relapsed/refractory diffuse large B-cell lymphoma treated with decitabine combined with ibrutinib in our hospital from April 2019 to June 2020 were retrospectively collected to evaluate the efficacy and adverse reactions.Results:A total of 12 patients were included.3 cases were achieved complete response,1 case was partial response,1 case was stable disease and 7 case were progressive disease.The objective response rate was 33.33%(4/12).The disease control rate was 41.67%(5/12).The median event free survival time was 1.5 months and the median overall survival time was 5 months.1 case underwent autolo-gous stem cell transplantation after achieving complete response and keep complete response.In terms of adverse reactions,the inci-dence of grade Ⅲ～Ⅳ haematological toxicity was 25.00%(3/12),and non-haematological toxicity mainly manifests as grade Ⅰ～Ⅱfatigue and rash.Grade Ⅰ～Ⅱ pulmonary infections was about 33.33%(4/12),and no cardiotoxicity occrred.Conclusion:Low-dose decitabine combined with ibrutinib is effective in the treatment of relapsed/refractory diffuse large B-cell lymphoma,with no impact on stem cell mobilisation and the safety profile is tolerable.
DecitabineIbrutinibRelapsed/RefractoryDiffuse large B-cell lymphoma
NETL
NSTL
万方数据
